期刊文献+

糖尿病肾病合并顽固性高血压降压治疗方法的研究

Study on the methodology of treatment of diabetic patients complicated with refratory hypetension
下载PDF
导出
摘要 目的探索糖尿病肾病合并顽固性高血压联合降压的优化方案。方法对36例糖尿病肾病合并顽固性高血压患者随机分为治疗组和对照组,观察两组治疗前后降压情况、副作用和实验证据变化。结果治疗组以卡托普利联合苯磺酸氨氯地平和螺内酯治疗4周,SBP和DBP以治疗前的162.0±15.2和92.1±8.6下降至128.8±6.8和81.2±5.9,略优于以倍他洛克联合苯磺酸氨氯地平和氢氯噻嗪的对照组,而且副作用少,耐受性好。结论卡托普利联合苯磺酸氨氯地平和螺内酯治疗高血压病既可减少药量,减少副作用,又可增加降压效应,值得进一步推广。 Objective To investigate the perfected antihypertensive treatment of diabetic nephropathy complicated with refractory hypertension. Methods There 36 diabetic nephropathy patients complicated with refractory hypertension were treated with two different therapies and the results were observed before and after the treatment. Results Effects of captopril combined with amlodipine and spironolactonum was superior to betaloc in combination with amlodipine and hydrochlorothiazide in addition to a light side effects and well tolerated. Conclusion Captopril combined with amlodipine and spironolactonum is effective for reatment of hypertension can reduce the quatity of drugs and side effects, worthy to be used for clinical treatment.
出处 《中国热带医学》 CAS 2008年第10期1720-1721,共2页 China Tropical Medicine
关键词 糖尿病肾病 顽固性高血压 卡托普利 苯磺酸氨氯地平 螺内酯 倍他洛克 氢氯噻嗪 联合用药 Diabetic nephropathy Refractory hypertension Captopril Amlodipine Spironolactonum Betaloc Hydro- chlorothiazide United antihypertensive treatment
  • 相关文献

参考文献9

  • 1Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report [ J]. JAMA, 2003,289:2560 - 2572.
  • 2European Society of Hypertension - European Society of Cardiology Guidelines Committee. 2007 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension[ J]. Joumal of Hypertension ,2007,25 : 1105 - 1187.
  • 3中国高血压防治指南起草委员会.中国高血压防治指南(2005年修订版).
  • 4The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an Angiotensin - Converting - Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High- Risk Patients[J]. N. Engl. J. Med, 2000, 342 : 145 - 153.
  • 5KM Fox and EURopean trial On reduction of cardiac events with Perin- dopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study) [ J ]. Lancet, 2003, 362:782 - 788.
  • 6Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta - analysis [ J ]. Lancet, 2001,358 : 1305 - 1315.
  • 7Bakris GL, Williams, Sworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a cones - nsus approach[ J]. Am J Kidney Dis, 2000,36:646 - 661.
  • 8Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding pefindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo - Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT - BPLA) : a multicentre randomised controlled trial[ J]. Lancet, 2005,366:895 ~ 906.
  • 9The Antilaypertensive and Lipid - Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high - risk hypertensive patients randomized to angiotension - converting enzyme inhibitor or calcium channel blocker vs diuretie [ J ]. JAMA, 2002,288 : 2981 -2997.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部